DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Clinical trials for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Drug access extended for cancer patients who responded well
Disease control CompletedThis study offers continued access to the drug tazemetostat for 58 people with certain cancers who previously benefited from it in other trials. The main goal is to track long-term safety and how long participants stay on the drug. It is not a cure but helps control the disease.
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated May 17, 2026 05:42 UTC
-
New drug shows promise against tough blood cancers in early trial
Disease control CompletedThis early-stage study tested a new drug called Purinostat Mesylate in 29 people with blood cancers like diffuse large B-cell lymphoma that had returned or stopped responding to standard treatments. The goal was to check the drug's safety, find the right dose, and see how the bod…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New combo shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis study tested a new drug called glofitamab combined with standard chemotherapy (R-ICE) in 43 adults with diffuse large B-cell lymphoma that returned after initial treatment. Participants were eligible for a stem cell transplant or CAR-T therapy. The goal was to see if the com…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug combo shows promise for Hard-to-Treat blood cancers
Disease control CompletedThis early-stage study tested a new drug called PRT2527, alone or combined with other drugs (zanubrutinib or venetoclax), in 86 people with blood cancers that returned or didn't respond to standard treatments. The main goals were to find a safe dose and check for side effects. Re…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Prelude Therapeutics • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
Spinal chemo shows promise in stopping brain spread of aggressive lymphoma
Prevention CompletedThis study tested a chemotherapy drug called thiotepa, given directly into the spinal fluid, to prevent a type of aggressive lymphoma (DLBCL) from spreading to the brain or spinal cord. It involved 31 high-risk adults and tracked how many developed brain involvement over two year…
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Prevention
Last updated May 15, 2026 11:54 UTC
-
CAR-T therapy Follow-Up study finds no new safety surprises
Knowledge-focused CompletedThis study followed 16 people who had already received a special immune cell treatment (CLBR001 CAR-T) for various blood cancers like lymphoma and leukemia. The goal was to see if any new or late side effects appeared over time and how long the treatment's effects lasted. It was …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Phase: PHASE1 • Sponsor: Calibr, a division of Scripps Research • Aim: Knowledge-focused
Last updated May 06, 2026 16:02 UTC
-
Scientists dig into old lymphoma cases to find genetic clues for future patients
Knowledge-focused CompletedThis study looked back at medical records and tissue samples from 555 patients with aggressive B-cell lymphomas. Researchers analyzed the genetic makeup of these cancers to see if specific genetic patterns could help classify the diseases more accurately and predict how patients …
Matched conditions: DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
Sponsor: Andrés José Maria Ferreri • Aim: Knowledge-focused
Last updated Apr 15, 2026 16:14 UTC